Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Edward F. McKone"'
Autor:
Sarah J. Morgan, Samantha L. Durfey, Sumedha Ravishankar, Peter Jorth, Wendy Ni, Duncan T. Skerrett, Moira L. Aitken, Edward F. McKone, Stephen J. Salipante, Matthew C. Radey, Pradeep K. Singh
Publikováno v:
JCI Insight, Vol 6, Iss 24 (2021)
A hallmark of chronic bacterial infections is the long-term persistence of 1 or more pathogen species at the compromised site. Repeated detection of the same bacterial species can suggest that a single strain or lineage is continually present. Howeve
Externí odkaz:
https://doaj.org/article/ae2c4456054541f9aec0c4f9751bc98b
Autor:
Andreas Jung, Annalisa Orenti, Fiona Dunlevy, Elina Aleksejeva, Egil Bakkeheim, Vladimir Bobrovnichy, Siobhán B. Carr, Carla Colombo, Harriet Corvol, Rebecca Cosgriff, Géraldine Daneau, Deniz Dogru, Pavel Drevinek, Andrea Dugac Vukic, Isabelle Fajac, Alice Fox, Stojka Fustik, Vincent Gulmans, Satenik Harutyunyan, Elpis Hatziagorou, Irena Kasmi, Hana Kayserová, Elena Kondratyeva, Uroš Krivec, Halyna Makukh, Kestutis Malakauskas, Edward F. McKone, Meir Mei-Zahav, Isabelle de Monestrol, Hanne Vebert Olesen, Rita Padoan, Tsitsino Parulava, Maria Dolores Pastor-Vivero, Luísa Pereira, Guergana Petrova, Andreas Pfleger, Liviu Pop, Jacqui G. van Rens, Milan Rodic´, Marc Schlesser, Valérie Storms, Oxana Turcu, Lukasz Woz´niacki, Panayiotis Yiallouros, Anna Zolin, Damian G. Downey, Lutz Naehrlich
Publikováno v:
ERJ Open Research, Vol 7, Iss 4 (2021)
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes. Methods In this observational study, the European Cystic Fibrosis Society Patient Registry collected
Externí odkaz:
https://doaj.org/article/3e2becbd44ec4bf582d17021b6083a88
Autor:
Samantha L. Durfey, Sudhakar Pipavath, Anna Li, Anh T. Vo, Anina Ratjen, Suzanne Carter, Sarah J. Morgan, Matthew C. Radey, Brenda Grogan, Stephen J. Salipante, Michael J. Welsh, David A. Stoltz, Christopher H. Goss, Edward F. McKone, Pradeep K. Singh
Publikováno v:
mBio, Vol 12, Iss 6 (2021)
ABSTRACT Drugs called CFTR modulators improve the physiologic defect underlying cystic fibrosis (CF) and alleviate many disease manifestations. However, studies to date indicate that chronic lung infections that are responsible for most disease-relat
Externí odkaz:
https://doaj.org/article/6014c178cf2145dba42af057cdbac508
Autor:
Katherine B. Hisert, Timothy P. Birkland, Kelly Q. Schoenfelt, Matthew E. Long, Brenda Grogan, Suzanne Carter, W. Conrad Liles, Edward F. McKone, Lev Becker, Anne M. Manicone, Sina A. Gharib
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundCFTR modulators decrease some etiologies of CF airway inflammation; however, data indicate that non-resolving airway infection and inflammation persist in individuals with CF and chronic bacterial infections. Thus, identification of therapi
Externí odkaz:
https://doaj.org/article/9bb3386b6d0b477b94c2d15b5d6ad5b6
Autor:
Katherine B. Hisert, Timothy P. Birkland, Kelly Q. Schoenfelt, Matthew E. Long, Brenda Grogan, Suzanne Carter, W. Conrad Liles, Edward F. McKone, Lev Becker, Anne M. Manicone
Publikováno v:
ERJ Open Research, Vol 6, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/9c0b01d418b14e5a8714aa95b00b6846
Autor:
Jennifer L. Taylor-Cousar, Marcus A. Mall, Bonnie W. Ramsey, Edward F. McKone, Elizabeth Tullis, Gautham Marigowda, Charlotte M. McKee, David Waltz, Samuel M. Moskowitz, Jessica Savage, Fengjuan Xuan, Steven M. Rowe
Publikováno v:
ERJ Open Research, Vol 5, Iss 2 (2019)
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator gene (CFTR) that result in diminished quantity and/or function of the CFTR anion channel. F508del-CFTR, the most common CF-causing mutation (found in ∼90% of
Externí odkaz:
https://doaj.org/article/22ef087b458643a6a8831a8c4b0bb4ea
Autor:
Ahmet Z Uluer, Gordon MacGregor, Pilar Azevedo, Veronica Indihar, Claire Keating, Marcus A Mall, Edward F McKone, Bonnie W Ramsey, Steven M Rowe, Ronald C Rubenstein, Jennifer L Taylor-Cousar, Elizabeth Tullis, Lael M Yonker, Chenghao Chu, Anna P Lam, Nitin Nair, Patrick R Sosnay, Simon Tian, Fredrick Van Goor, Lakshmi Viswanathan, David Waltz, Linda T Wang, Yingmei Xi, Joanne Billings, Alexander Horsley, Edward F. Nash, Marleen Bakker, Renske van der Meer, Petrus Merkus, Christof Majoor, Karen McCoy, Krishna Pancham, James Tolle, Bryon Quick, Ahmet Uluer, Emily DiMango, Adupa Rao, Santiago Reyes, Ross Klingsberg, Celeste Barreto, Victor Ortega, Donna Willey-Courand, Carsten Schwarz, Sivagurunathan Sutharsan, Rainald Fischer, Jane Davies, Jamie Duckers, Simon Doe, Harry Heijerman, George M. Solomon, Christian Merlo, Jennifer Griffonnet, Joseph Pilewski, Jordan Dunitz, Saba Sheikh, Ronald C. Rubenstein, Daniel B. Rosenbluth, Theodore Liou, Maria Indihar, Lael Yonker, Samya Nasr, Cynthia D. Brown, Gregory S. Sawicki, Jennifer Ruddy, Bryan Garcia, Andrew Braun, Alex H. Gifford, Nighat Mehdi, Maria Tupayachi Ortiz, Raksha Jain, Francisco J. Calimano, Jimmy Johannes, Cori L. Daines, Jason Fullmer, Joel Mermis, Christopher Barrios, Ngoc Ly, Brian P. Casserly, Stephan Eisenmann, Helge Hebestreit, Alexander Kiefer, Daniel Peckham, Martin Ledson, Eva Van Braeckel, Noel Gerard McElvaney, Edward McKone, Barry Plant, Lucy Burr, Daniel J. Smith, Peter Middleton, John Wilson
Publikováno v:
The Lancet Respiratory Medicine, 11(6), 550-562. Elsevier Limited
VX18-121-101 & VX18-561-101 Study Groups 2023, ' Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis : randomised, double-blind, controlled, phase 2 trials ', The Lancet Respiratory Medicine, vol. 11, no. 6, pp. 550-562 . https://doi.org/10.1016/S2213-2600(22)00504-5
LANCET RESPIRATORY MEDICINE
VX18-121-101 & VX18-561-101 Study Groups 2023, ' Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis : randomised, double-blind, controlled, phase 2 trials ', The Lancet Respiratory Medicine, vol. 11, no. 6, pp. 550-562 . https://doi.org/10.1016/S2213-2600(22)00504-5
LANCET RESPIRATORY MEDICINE
Background: Elexacaftor–tezacaftor–ivacaftor has been shown to be safe and efficacious in people with cystic fibrosis and at least one F508del allele. Our aim was to identify a novel cystic fibrosis transmembrane conductance regulator (CFTR) modu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b19fd4ef9823a3f92122d18b15dec4
https://research.vumc.nl/en/publications/0a8b171c-28b7-4da9-8e4a-5749733cacf9
https://research.vumc.nl/en/publications/0a8b171c-28b7-4da9-8e4a-5749733cacf9
Autor:
Gregory S. Sawicki, Michael W. Konstan, Edward F. McKone, Richard B. Moss, Barry Lubarsky, Ellison Suthoff, Stefanie J. Millar, David J. Pasta, Nicole Mayer-Hamblett, Christopher H. Goss, Wayne J. Morgan, Margaret E. Duncan, Yoojung Yang
Publikováno v:
Pulmonary Therapy. 8:385-395
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Approximately 5% of people with CF have residual function (RF) CFTR mutations that result in partially retained CFTR
Autor:
Suzanne C. Carter, Alessandro N. Franciosi, Kate M. O’Shea, Orla M. O’Carroll, Ashutosh Sharma, Aoife Bell, Brian Keogan, Paul O’Reilly, Suzie Coughlan, Sheonagh M. Law, Robert D. Gray, Katherine B. Hisert, Pradeep K. Singh, Gordon Cooke, Brenda Grogan, Cillian F. De Gascun, Charles G. Gallagher, Trevor T. Nicholson, Bradley S. Quon, Edward F. McKone
Publikováno v:
Annals of the American Thoracic Society. 19:1818-1826
Publikováno v:
Journal of Cystic Fibrosis. 21:562-573
Acute exacerbations of Cystic Fibrosis (AECF) are associated with significant morbidity. Recommendations are to treat for 2-3 weeks despite limited data. Spirometry is a measure of clinical response yet appears to plateau at 7-10 days. While duration